Anti-cancer properties of canolol

Canolol, a potent antioxidant derived from rapeseed oil during heat processing, has shown promising anticancer properties. It is more effective than common antioxidants like vitamin C and α-tocopherol in scavenging free radicals and reducing inflammation. Canolol suppresses pro-inflammatory cytokines and enzymes such as TNF-α, IL-1β, iNOS, and COX-2. In gastric cancer models, it reduces tumor incidence, inhibits cell proliferation, and promotes apoptosis via downregulation of COX-2 and the PI3K/Akt pathway. Canolol also demonstrated strong anti-cancer activity in cervical cancer by inducing apoptosis and reducing tumor volume in HeLa cell xenografts. For colon cancer, it suppressed inflammation and reduced tumor formation in a colitis-related cancer model. Although tumor size was not significantly decreased, it showed preventive effects by modulating inflammatory gene expression. In breast cancer studies, canolol reduced MCF-7 cell viability with potential cytotoxic effects, though mechanisms remain unclear. Liver cancer investigations revealed that canolol modulates apoptotic pathways depending on concentration, with lower doses inhibiting apoptosis and higher doses inducing it. These effects were linked to regulation of Bcl-2, Bax, caspase-3, and p53 in HepG2 cells. Across studies, canolol’s anticancer mechanisms include inducing apoptosis, oxidative stress, and modulation of signaling pathways. Its benefits are supported by both in vitro and animal studies, but human clinical data are lacking. Concerns remain about its bioavailability and metabolic stability in the human body. More research is needed to confirm its efficacy in humans and determine optimal dosages. Nevertheless, canolol holds promise as a natural agent for cancer prevention and treatment in food, nutraceutical, and medical applications.